Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

PL 8331

Drug Profile

PL 8331

Alternative Names: PL-8331

Latest Information Update: 21 Apr 2023

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Palatin Technologies
  • Class Anti-inflammatories; Eye disorder therapies
  • Mechanism of Action Melanocortin type 1 receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Preclinical Choroidal neovascularisation; Diabetic retinopathy
  • Phase Unknown Dry eyes

Most Recent Events

  • 18 Apr 2023 Pharmacodynamics data from a preclinical study in Diabetic retinopathy and Uveitis released by Palatin Technologies
  • 30 Nov 2021 Palatin Technologies receives patent allowance for method of treating cytokine storm using melanocortin-specific peptide in USA in November 2021
  • 29 Sep 2021 PL 8331 is available for licensing as of 29 Sep 2021. http://www.palatin.com
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top